Landscapes / Targets
KRAS G12D
22 drugs act on KRAS G12D, in 58 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs22
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Hengrui · Public 600276.SS |
Phase 3 | Mar 2027Phase 1/2 trial completes | ||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Pancreatic Cancer and 2 more | ||||
| Open drug page | |||||
KRAS G12D inhibitor |
GenFleet Therapeutics +1 |
Phase 3 | 30 Apr 2027Phase 2 trial completes | ||
| Next date | 30 Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | Colorectal Cancer, G12D Mutated KRAS and 13 more | ||||
| Open drug page | |||||
KRAS G12D inhibitor |
Phase 3 | Jun 2027Phase 1/2 trial completes | |||
| Next date | Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | PDAC, Pancreatic Ductal Adenocarcinoma (PDAC) and 31 more | ||||
| Open drug page | |||||
— |
Phase 3 | 15 Sep 2028Phase 3 trial completes | |||
| Next date | 15 Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumors, Hepatic Insufficiency and 3 more | ||||
| Open drug page | |||||
KRAS G12D degrader |
Phase 3 | 31 Aug 2029Phase 3 trial completes | |||
| Next date | 31 Aug 2029 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumor, Pancreatic Cancer and 3 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Nov 2026soonPhase 2 trial completes | |||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma (PDAC), Food Effect and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Oct 2027Phase 1/2 trial completes | |||
| Next date | 30 Oct 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Malignant Neoplasm | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Pancreatic Ductal Adenocarcinoma, Colorectal Cancer and 11 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Solid Tumor, Non-small Cell Lung Cancer and 3 more | ||||
| Open drug page | |||||
— |
Phase 1 | 15 Dec 2026soonPhase 1 trial completes | |||
| Next date | 15 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumor | ||||
| Open drug page | |||||
— |
Phase 1 | 27 Mar 2027Phase 1 trial completes | |||
| Next date | 27 Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | 1 Apr 2027Phase 1 trial completes | |||
| Next date | 1 Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | 1 Jul 2027Phase 1 trial completes | |||
| Next date | 1 Jul 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
— |
AstraZeneca · Public AZN |
Phase 1 | 30 Aug 2027Phase 1 trial completes | ||
| Next date | 30 Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Colorectal Carcinoma and 3 more | ||||
| Open drug page | |||||
— |
AstraZeneca · Public AZN |
Phase 1 | 30 Aug 2027Phase 1 trial completes | ||
| Next date | 30 Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Colorectal Carcinoma and 3 more | ||||
| Open drug page | |||||
— |
Phase 1 | 11 Jan 2028Phase 1 trial completes | |||
| Next date | 11 Jan 2028 · Phase 1 trial completes | ||||
| Also tested for | KRAS P.G12D | ||||
| Open drug page | |||||
— |
Eli Lilly · Public LLY |
Phase 1 | Mar 2028Phase 1 trial completes | ||
| Next date | Mar 2028 · Phase 1 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer and 1 more | ||||
| Open drug page | |||||
— |
Roche · Public ROG.SW |
Phase 1 | 31 May 2028Phase 1 trial completes | ||
| Next date | 31 May 2028 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumor, Colorectal Neoplasms and 1 more | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 1 | May 2028Phase 1 trial completes | ||
| Next date | May 2028 · Phase 1 trial completes | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Apr 2029Phase 1 trial completes | |||
| Next date | 30 Apr 2029 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 22 of 22 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026